reports
- Dave Nicoski
- Ross LaDuke
XONE EXONE CO
SPLK SPLUNK INC.
RUN SUNRUN INC.
RGNX REGENXBIO INC.
REGN REGENERON PHARMACEUTICALS INC.
NRG NRG ENERGY INC.
LXRX LEXICON PHARMACEUTICALS INC.
LGND LIGAND PHARMACEUTICALS INCORPORATED
K KELLOGG COMPANY
EDIT EDITAS MEDICINE INC.
CHMA CHIASMA
BMRN BIOMARIN PHARMACEUTICAL INC.
AXSM AXSOME THERAPEUTICS
ASPS ALTISOURCE PORTFOLIO SOLUTIONS S.A.
PI IMPINJ INC.
RETA REATA PHARMACEUTICALS INC. CLASS A
TNDM TANDEM DIABETES CARE
APPN APPIAN
RGCO RGC RESOURCES
SAIL SAILPOINT TECHNOLOGIES
APLT APPLIED THERAPEUTICS
NOVA SUNNOVA ENERGY INTERNATIONAL
VERO VENUS CONCEPT
MGNI MAGNITE INC
PCVX VAXCYTE
U UNITY SOFTWARE
MAXN MAXEON SOLAR TECHNOLOGIES
Chiasma Announces Submission of Marketing Authorization Application fo...
Chiasma Announces Submission of Marketing Authorization Application for MYCAPSSA® to the European Medicines Agency Submission supported by previously announced data from Phase 3 MPOWERED™ study NEEDHAM, Mass., June 28, 2021 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), (“Chiasma” or the “Company”), a commercial-stage biopharmaceutical company utilizing its delivery platform technology to develop and commercialize oral therapies to improve the lives of patients with rare diseases currently treated with burdensome and painful injections, today announced that it has submitted a Marketi...
Chiasma Presents Positive Patient-Reported Outcomes Data from its MPOW...
Chiasma Presents Positive Patient-Reported Outcomes Data from its MPOWERED™ Phase 3 Trial Comparing MYCAPSSA® to Long-Acting Injectables for the Maintenance Treatment of Adults with Acromegaly --Data presented at AACE 2021 demonstrate patient quality of life and work productivity significantly improved in patients transitioning from injectable SSAs to MYCAPSSA®-- NEEDHAM, Mass., May 27, 2021 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), (“Chiasma” or the “Company”) today presented patient-reported outcomes (PROs) data from its MPOWERED™ Phase 3 trial demonstrating that study patient...
Chiasma to Present Encore and New Data from MPOWERED™ Phase 3 Trial at...
Chiasma to Present Encore and New Data from MPOWERED™ Phase 3 Trial at Upcoming e-ECE and AACE Virtual Conferences -- New clinical data accepted for oral and e-Poster presentation at AACE -- -- e-ECE clinical data previously presented at Endocrine Society’s 2021 annual meeting -- NEEDHAM, Mass., May 20, 2021 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), (“Chiasma” or the “Company”), a commercial-stage biopharmaceutical company utilizing its delivery platform technology to develop and commercialize oral therapies to improve the lives of patients with rare diseases currently t...
Chiasma Reports First Quarter Financial Results and Announced Agreemen...
Chiasma Reports First Quarter Financial Results and Announced Agreement to Merge with Amryt Announced agreement to merge with Amryt Combination to create a global commercial stage rare and orphan disease leader with a diversified portfolio of therapies and a meaningful late-stage development pipeline Q1 2021 Net Product Revenues of $1.9M, a 100% increase over Q4 2020 Achieved payor coverage of MYCAPSSA for over 185 million lives Submitted an Investigational New Drug (IND) application for the study of MYCAPSSA in patients with carcinoid syndrome associated with Neuroendocrine Tum...
Amryt Pharma to Acquire Chiasma, Inc. to Further Strengthen Global Lea...
Amryt Pharma to Acquire Chiasma, Inc. to Further Strengthen Global Leadership in Rare and Orphan Diseases - Combined business will have three approved commercial products, lomitapide (Lojuxta®/Juxtapid®), metreleptin (Myalept®/ Myalepta®), octreotide (MYCAPSSA®) and a robust clinical pipeline - Lead pipeline product Oleogel-S10*(Filsuvez®) under regulatory review in the US and EU - Deal expected to pave a path to a combined potential $1BN peak revenue for Amryt - The acquisition is expected to deliver estimated annual cost synergies of approximately $50M and be revenue and EBITDA a...
Chiasma to Report First Quarter Financial Results on May 6, 2021
Chiasma to Report First Quarter Financial Results on May 6, 2021 NEEDHAM, Mass., April 29, 2021 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial stage biopharmaceutical company, today announced that it will host a live conference call and audio webcast on Thursday, May 6, 2021 at 5:00 pm Eastern Time to discuss financial results for the quarter ended March 31, 2021 and to provide a business update. Conference Call Details: Thursday May 6, 2021, 5:00 PM ET Domestic:800-909-4761International:312-281-2942Conference ID:21993564Webcast: A live audio webcast of the call may also...
Chiasma Presents Long-Term Safety and Efficacy Data from the Open-Labe...
Chiasma Presents Long-Term Safety and Efficacy Data from the Open-Label Extension Study of its CHIASMA OPTIMAL Phase 3 Trial Evaluating MYCAPSSA® in Patients with Acromegaly at ENDO 2021 --93% of all patients who enrolled as a responder to MYCAPSSA® maintained their biochemical response at the end of the 48-week open-label extension (OLE) period-- --Safety profile during the OLE was generally consistent with the safety observed in the CHIASMA OPTIMAL trial NEEDHAM, Mass., March 22, 2021 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), (“Chiasma” or the “Company”), a commercial-stage b...
Chiasma Presents New Positive Data for MYCAPSSA from Phase 3 Trial MPO...
Chiasma Presents New Positive Data for MYCAPSSA from Phase 3 Trial MPOWERED™ for the Maintenance Treatment of Acromegaly at ENDO 2021 --Data supports MYCAPSSA® as non-inferior to long-acting injectable somatostatin receptor ligands (iSRLs)-- --Data demonstrated patients taking MYCAPSSA had significant improvement in acromegaly related symptoms and patient reported outcomes after switching from iSRLs-- NEEDHAM, Mass., March 20, 2021 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), (“Chiasma” or the “Company”), a commercial-stage biopharmaceutical company utilizing its delivery platform ...
Chiasma to Present New Data from Two Phase 3 Trials, CHIASMA OPTIMAL a...
Chiasma to Present New Data from Two Phase 3 Trials, CHIASMA OPTIMAL and MPOWERED™, at ENDO 2021 -- One oral presentation and five late-breaking posters accepted -- NEEDHAM, Mass., March 10, 2021 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), (“Chiasma” or the “Company”), a commercial-stage biopharmaceutical company utilizing its delivery platform technology to develop and commercialize oral therapies to improve the lives of patients with rare diseases currently treated with burdensome and painful injections, as evidenced by its recent approval of MYCAPSSA as the first and only oral t...
Chiasma Reports Fourth Quarter and Full-Year 2020 Financial Results an...
Chiasma Reports Fourth Quarter and Full-Year 2020 Financial Results and Provides Corporate Update Phased launch of MYCAPSSA® progressing with 2020 net product revenue of $1.1 million Achieved payor coverage of MYCAPSSA for over 150 million lives Company to host conference call today, March 4, 2021 at 5:00pm ET NEEDHAM, Mass., March 04, 2021 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial stage biopharmaceutical company utilizing its delivery platform technology to develop and commercialize oral therapies to reduce the burden of chronic injections for people with rare dis...
Chiasma to Participate in the H.C. Wainwright Global Life Sciences Con...
Chiasma to Participate in the H.C. Wainwright Global Life Sciences Conference NEEDHAM, Mass., March 02, 2021 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial-stage biopharmaceutical company, today announced that management will present a company overview at the H.C. Wainwright Global Life Sciences Conference, which is being held Tuesday, March 9th - Wednesday, March 10th, 2021. The presentation will be available on demand on H.C. Wainwright’s conference portal beginning at 7:00 am on Tuesday, March 9th, 2021. About ChiasmaChiasma is a commercial-stage biopharmaceu...
Chiasma to Report Fourth Quarter 2020 Results on March 4
Chiasma to Report Fourth Quarter 2020 Results on March 4 Company to host conference call and webcast at 5:00 p.m. ET NEEDHAM, Maine, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial stage biopharmaceutical company, today announced that it will host a conference call and live audio webcast on Thursday, March 4, 2021 at 5:00 pm Eastern Time to discuss financial results for the quarter and year ended December 31, 2020 and to provide a business update. Conference Call Details Thursday, March 4th @ 5:00 pm Eastern Time Domestic:877-407-4018International:201...
Chiasma Announces Hiring of John Doyle as Chief Financial Officer
Chiasma Announces Hiring of John Doyle as Chief Financial Officer Appointment provides extensive commercial-stage public company financial leadership experience NEEDHAM, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial-stage biopharmaceutical company utilizing its delivery platform technology to develop and commercialize oral therapies to improve the lives of patients with rare diseases currently treated with burdensome and painful injections, as evidenced by its recent phased launch of MYCAPSSA® as the first oral therapy for the treatment of acromega...
Chiasma Provides Corporate Update and Previews Expected 2021 Milestone...
Chiasma Provides Corporate Update and Previews Expected 2021 Milestones MYCAPSSA® launch in US continuing to gain traction with physicians, patients, and payers MYCAPSSA® EMA submission for EU marketing approval on track for mid-2021 following positive results of MPOWERED Phase 3 clinical trial NEEDHAM, Mass., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial-stage biopharmaceutical company utilizing its delivery platform technology to develop and commercialize oral therapies to improve the lives of patients with rare diseases currently treated with burdensom...
- Jonathan Moreland
- Jonathan Moreland
SYNL SYNALLOY CORP.
STFC STATE AUTO FINANCIAL CORP.
SREV SERVICESOURCE INTERNATIONAL INC.
MACK MERRIMACK PHARMACEUTICALS INC
EIG EMPLOYERS HOLDINGS INC.
CVCY CENTRAL VALLEY COMMUNITY BANCORP
CTG COMPUTER TASK GROUP INC.
COTY COTY INC. CLASS A
CHMA CHIASMA
BKH BLACK HILLS CORPORATION
AFG AMERICAN FINANCIAL GROUP INC.
AAT AMERICAN ASSETS TRUST INC.
TRST TRUSTCO BANK CORP.
FTK FLOTEK INDUSTRIES INC.
PBFX PBF LOGISTICS LP
SPOK SPOK HOLDINGS
FLXS FLEXSTEEL INDUSTRIES INC.
EPD ENTERPRISE PRODUCTS PARTNERS L.P.
ESP ESPEY MANUFACTURING & ELECTRONICS CORP.
HFBL HOME FEDERAL BANCORP INC. OF LOUISIANA
CNBKA CENTURY BANCORP INC. CL A
BKI BLACK KNIGHT INC.
CNX CONSOL ENERGY INC.
VBFC VILLAGE BANK AND TRUST FINANCIAL
KRMD REPRO MED SYSTEMS
GIM TEMPLETON GLOBAL INCOME FUND
VTA INVESCO DYNAMIC CREDIT OPPORTU
ORGO ORGANOGENESIS HOLDINGS (A)
LSYN LIBERATED SYNDICATION
PSTI PLURISTEM THERAPEUTICS INC
BCSF BAIN CAPITAL SPECIALTY FINANCE
CVLB CONVERSION LABS
ATCX INC.
FSLF ATLAS TECHNICAL CONSULTANTS INC (A)
FTSI THL CREDIT SENIOR LOAN FUND
BSPK FTS INTERNATIONAL INC. CLASS A
FPI BESPOKE EXTRACTS
MPLN INC.
COHN BVD CO
DMAC MULTIPLAN CORP CLASS A
COHEN AND COMPANY
DIAMEDICA THERAPEUTICS INC.
- Jonathan Moreland
Chiasma Inc: 1 director bought
A director at Chiasma Inc bought 120,000 shares at 4.004USD and the significance rating of the trade was 95/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly s...
Chiasma to Participate in Two Investor Conferences in December
Chiasma to Participate in Two Investor Conferences in December NEEDHAM, Mass., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial-stage biopharmaceutical company utilizing its delivery platform technology to develop and commercialize oral therapies to improve the lives of patients with rare diseases on burdensome and painful injections, today announced that management will be presenting and participating in investor meetings at both the Piper Sandler Healthcare Conference as well as the Evercore ISI HealthCONx Conference. Details for each conference are as follow...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.